Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonar...
Saved in:
Published in | Journal of Cancer Vol. 11; no. 11; pp. 3407 - 3415 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Ivyspring International Publisher Pty Ltd
01.01.2020
Ivyspring International Publisher |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice.
: Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied.
: 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment.
: The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death. |
---|---|
AbstractList | Introduction
: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice.
Materials & Methods
: Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied.
Results
: 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment.
Conclusions
: The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death. : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. : Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. : 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. : The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death. Introduction: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by smoking and the use of tobacco products. However, other factors such as asbestos, air pollution and chronic infections can contribute to pulmonary carcinogenesis. Lung cancer is divided into two broad histological categories, which develop and spread different small cell lung carcinomas and non-small cell lung carcinomas. The treatment options for lung cancer include surgery, radiotherapy, chemotherapy and targeted treatments. Tumor induced immune suppression is vital for malignant progression. Immunotherapies act by strengthening the patient's innate tendency for an immune response and give positive promise to patients with non-small cell lung cancer and small cell lung cancer. Immune checkpoint inhibitors are a new approach to cancer therapies. Just as immune therapies include a new approach to cancer biology, the toxicities associated with these factors have created new challenges in clinical practice. Materials & Methods: Patients (218) aged 40-80 years were treated with either chemotherapy or immunotherapy. Their response to treatment and any subsequent adverse drug reactions were studied. Results: 69% of patients were treated with chemotherapy and 31% were treated with immunotherapy. The type of treatment had a statistically significant effect on the undesirable effects of the treatment. Conclusions: The type of treatment was statistically significant in responding to the treatment and treatment side effects but not in the rate of death. |
Author | Goganau, Alexandru Marian Pilikidou, Maria Kyrka, Konstantina Kesisoglou, Isaak Papazisis, George Heva, Anta Baka, Sofia Papadopoulou, Souzana Platanas, Michalis Petanidis, Savvas Porpodis, Konstantinos Tryfon, Stavros Boniou, Konstantina Kyrka, Krystallia Sardeli, Chrisanthi Kosmidis, Christoforos Sapalidis, Konstantinos Zaric, Bojan Koulouris, Charilaos Tsakiridis, Kosmas Miziou, Angeliki Tsiouda, Theodora Giannakidis, Dimitrios Apostolidis, Georgios Zarogoulidis, Paul Sevva, Christina Tsingerlioti, Zoi Perin, Branislav Vagionas, Anastasios |
AuthorAffiliation | 3 Pulmonary Department, G. “Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece 5 General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania 7 Pulmonary Department (NHS), G.H. “G. Papanikolaou” Thessaloniki, Thessaloniki, Greece 1 Pulmonary Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece 4 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece 8 Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece 6 Thoracic Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece 2 Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece 9 Oncology Department, “Interbalkan” European Medical Center, Thessaloniki, Greece 10 Institute for Pulmonary Diseases of Vojvodina, Facu |
AuthorAffiliation_xml | – name: 1 Pulmonary Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece – name: 5 General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania – name: 2 Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece – name: 10 Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia – name: 6 Thoracic Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece – name: 7 Pulmonary Department (NHS), G.H. “G. Papanikolaou” Thessaloniki, Thessaloniki, Greece – name: 4 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – name: 8 Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece – name: 3 Pulmonary Department, G. “Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece – name: 9 Oncology Department, “Interbalkan” European Medical Center, Thessaloniki, Greece – name: 11 Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation |
Author_xml | – sequence: 1 givenname: Theodora surname: Tsiouda fullname: Tsiouda, Theodora organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 2 givenname: Chrisanthi surname: Sardeli fullname: Sardeli, Chrisanthi organization: Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 3 givenname: Konstantinos surname: Porpodis fullname: Porpodis, Konstantinos organization: Pulmonary Department, G. "Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 4 givenname: Maria surname: Pilikidou fullname: Pilikidou, Maria organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 5 givenname: Georgios surname: Apostolidis fullname: Apostolidis, Georgios organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 6 givenname: Krystallia surname: Kyrka fullname: Kyrka, Krystallia organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 7 givenname: Angeliki surname: Miziou fullname: Miziou, Angeliki organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 8 givenname: Konstantina surname: Kyrka fullname: Kyrka, Konstantina organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 9 givenname: Zoi surname: Tsingerlioti fullname: Tsingerlioti, Zoi organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 10 givenname: Souzana surname: Papadopoulou fullname: Papadopoulou, Souzana organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 11 givenname: Anta surname: Heva fullname: Heva, Anta organization: Pulmonary Department, "Theageneio" Cancer Hospital, Thessaloniki, Greece – sequence: 12 givenname: Charilaos surname: Koulouris fullname: Koulouris, Charilaos organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 13 givenname: Dimitrios surname: Giannakidis fullname: Giannakidis, Dimitrios organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 14 givenname: Konstantina surname: Boniou fullname: Boniou, Konstantina organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 15 givenname: Isaak surname: Kesisoglou fullname: Kesisoglou, Isaak organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 16 givenname: Anastasios surname: Vagionas fullname: Vagionas, Anastasios organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 17 givenname: Christoforos surname: Kosmidis fullname: Kosmidis, Christoforos organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 18 givenname: Christina surname: Sevva fullname: Sevva, Christina organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 19 givenname: George surname: Papazisis fullname: Papazisis, George organization: Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece – sequence: 20 givenname: Alexandru Marian surname: Goganau fullname: Goganau, Alexandru Marian organization: General Surgery Clinic 1, University of Medicine and Pharmacy of Craiova, Craiova County Emergency Hospital, Craiova, Romania – sequence: 21 givenname: Konstantinos surname: Sapalidis fullname: Sapalidis, Konstantinos organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece – sequence: 22 givenname: Kosmas surname: Tsakiridis fullname: Tsakiridis, Kosmas organization: Thoracic Surgery Department, "Interbalkan" European Medical Center, Thessaloniki, Greece – sequence: 23 givenname: Stavros surname: Tryfon fullname: Tryfon, Stavros organization: Pulmonary Department (NHS), G.H. "G. Papanikolaou" Thessaloniki, Thessaloniki, Greece – sequence: 24 givenname: Michalis surname: Platanas fullname: Platanas, Michalis organization: Urology Department (NHS), General Hospital of Giannitsa, Giannitsa, Greece – sequence: 25 givenname: Sofia surname: Baka fullname: Baka, Sofia organization: Oncology Department, "Interbalkan" European Medical Center, Thessaloniki, Greece – sequence: 26 givenname: Bojan surname: Zaric fullname: Zaric, Bojan organization: Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia – sequence: 27 givenname: Branislav surname: Perin fullname: Perin, Branislav organization: Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia – sequence: 28 givenname: Savvas surname: Petanidis fullname: Petanidis, Savvas organization: Department of Pulmonology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation – sequence: 29 givenname: Paul surname: Zarogoulidis fullname: Zarogoulidis, Paul organization: 3rd Department of Surgery, "AHEPA" University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32231747$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkU9P3DAQxa2KqtAtB74AssSlPQRsjx3HFyQUaEFa0QNwtpzshM1qY2_thMK3r8ufFa0P49HMT09v9D6THR88EnLA2bHmip2sWncsGTflB7LHK9CFKUu5867fJfsprVh-YISW8InsghDAtdR7pL_BR3redx1G9C0m6vyCni0eMCakF3ncjok2OP5G9LRe4hDGJUa3eXoGr4Zh8ttJFyK9Dr64Gdx6TWvMZT75e1q7rBy_kI-dWyfcf_1n5O77xW19Wcx__riqz-ZFKxmMRdUKo1TJuWaN0h2KygFq1QkEAQ0o6QyohRAdY4YzANVoaBoFEplEgyXMyOmL7mZqBly06Mfo1nYT-8HFJxtcb__d-H5p78OD1cxokz3MyNdXgRh-TZhGO_Spzdc4j2FKVkClhM4eTUaP_kNXYYo-n2eFMhVIVpUyU99eqDaGlCJ2WzOc2b8Z2pyhfc4ws4fv3W_Jt8TgDxtBmCo |
CitedBy_id | crossref_primary_10_3389_fmolb_2023_1297198 crossref_primary_10_1016_j_bulcan_2023_02_010 crossref_primary_10_1080_14740338_2023_2243220 crossref_primary_10_1016_j_intimp_2023_109713 crossref_primary_10_3389_fonc_2023_1210297 crossref_primary_10_3389_fonc_2024_1307836 crossref_primary_10_1002_cnr2_1739 crossref_primary_10_1016_j_jmb_2021_167221 crossref_primary_10_1155_2021_8852261 crossref_primary_10_3390_curroncol29110637 crossref_primary_10_3390_medicina58121779 crossref_primary_10_1371_journal_pone_0240633 |
ContentType | Journal Article |
Copyright | The author(s). 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The author(s) 2020 |
Copyright_xml | – notice: The author(s). – notice: 2020. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The author(s) 2020 |
DBID | NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.7150/jca.40196 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Health Medical collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X7 name: ProQuest_Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1837-9664 |
EndPage | 3415 |
ExternalDocumentID | 10_7150_jca_40196 32231747 |
Genre | Journal Article |
GroupedDBID | --- 53G 5VS 7X7 8FI 8FJ ABDBF ABUWG ADBBV ADRAZ AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU DIK E3Z FYUFA GROUPED_DOAJ HMCUK HYE IPNFZ KQ8 M48 M~E NPM O5R O5S OK1 PGMZT PIMPY RIG RPM UKHRP AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c403t-8c295561170b57fe28a3e75f2e323b354a935d22f00910335b73bb534e04e9e63 |
IEDL.DBID | RPM |
ISSN | 1837-9664 |
IngestDate | Tue Sep 17 21:28:06 EDT 2024 Fri Aug 16 00:46:30 EDT 2024 Thu Oct 10 19:30:57 EDT 2024 Fri Aug 23 01:26:21 EDT 2024 Sat Sep 28 08:28:18 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | adverse effects chemotherapy Lung cancer immunotherapy |
Language | English |
License | The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c403t-8c295561170b57fe28a3e75f2e323b354a935d22f00910335b73bb534e04e9e63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have declared that no competing interest exists. |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097940/ |
PMID | 32231747 |
PQID | 2598340864 |
PQPubID | 5263174 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7097940 proquest_miscellaneous_2385275569 proquest_journals_2598340864 crossref_primary_10_7150_jca_40196 pubmed_primary_32231747 |
PublicationCentury | 2000 |
PublicationDate | 2020-01-01 |
PublicationDateYYYYMMDD | 2020-01-01 |
PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Wyoming – name: Sydney |
PublicationTitle | Journal of Cancer |
PublicationTitleAlternate | J Cancer |
PublicationYear | 2020 |
Publisher | Ivyspring International Publisher Pty Ltd Ivyspring International Publisher |
Publisher_xml | – name: Ivyspring International Publisher Pty Ltd – name: Ivyspring International Publisher |
SSID | ssj0000392743 |
Score | 2.320233 |
Snippet | : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are caused by... Introduction: Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are... Introduction : Lung cancer remains the leading cause of cancer mortality in men and women and around the world. Approximately 90% of cases of lung cancer are... |
SourceID | pubmedcentral proquest crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 3407 |
SubjectTerms | Anemia Asthma Autoimmune diseases Cancer therapies Cardiovascular disease Chemotherapy Chronic illnesses Chronic obstructive pulmonary disease Diabetes Gastroesophageal reflux Gender Gene expression Heart failure Hypertension Hyperthyroidism Hypothyroidism Immunotherapy Infections Kinases Ligands Lung cancer Patients Research Paper Stroke Ultrasonic imaging Womens health |
SummonAdditionalLinks | – databaseName: Health Medical collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9wwDLcYSNNeEGMbFG5TmPbakeajaZ8QOkA3xN0LQ7q3Kml9AgQ94A4J_nucNtftQOKlD02qtnZs_2I7NsCv1EeHnONxKZSOlXMmdrkmcbc2EWlOMtKUzB-O0sGFOh3rcXC4zUJa5UInNoq6mpbeR75PMD2TigC4Ori7j33XKB9dDS00PsBaInjqU7rM2HQ-Fk7GnyxkW1DIEPTZvy7tb-VLwiyboTfY8nWK5H8252QD1gNYZIctdz_DCtab8HEYwuFf4Oocn9hRaHFCAs9sXbGmxfIMWVuXeMZCJhbzpQHCcavnZuIffzSku0PglY2mdXx-a29uWB_pckaKgPX9snj4Chcnx3_7gzj0TohLxeU8zkqR-86XieFOmwmKzEo0eiJQCumkVjaXuhJiwj1gkFI7I53TUiFXmGMqv8FqPa1xG1hlSl4lmFhUmRKWnkabTQhHGoEEL2UEPxekLO7aEhkFbS08vQuid9HQO4LegshFkJJZ8Y-nEex1w7S-fdDC1jh9pDky08LQr-QRbLU86d5CyojgjzIRmCVudRN87ezlkfrqsqmhbXhOmojvvP9Zu_BJ-P1143Lpwer84RG_EwiZux_NSnsBA9Lc4Q priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3JTsMwEB2VIiEuiJ2wySCugdRLnJwQKqCCgAtU4hbZ7VQUlRS6SPTvGSduRYEDlxxiW1bG9vi9ePwG4CR2p0PWRmGLSxVKa3VoU0XL3Zgaj1NaI4Vk_v1D3GjK22f1XIFpjk1vwOGf1M7lk2oOeqefH5NzWvCEX0814ZmzV-L-0um8LMAil0TQXQSfR_mFQyYM4EPtiY45PUpZagzNt57fmX7BzZ9Rk9-2oetVWPH4kV2UA74GFczXYenen5BvQPcRP9mlz3pCPoCZvM2KrMtDZKVU8ZD54Czm1AL8DaxJUfHG3RaZvSE8yx76efj4Zno9Vkd63JFvYHU3Uwab0Ly-eqo3Qp9OIWzJSIzCpMVTlwyzpiOrdAd5YgRq1eEouLBCSZMK1ea8EzkMIYSyWlirhMRIYoqx2IJq3s9xB1hbt6J2DWsGZSK5odZokg5BS82REKcI4Hhqyuy9VM3IiG04e2dk76ywdwD7UyNn03HPiI0lQhLPkgEczYppyrtzDJNjf0x1RKK4pk9JA9gux2TWC_knQkRSB6DnRmtWwclpz5fk3ZdCVltHKTmnaPcf_e7BMne8u_gVsw_V0WCMBwRORvawmHpffNbiiA priority: 102 providerName: Scholars Portal |
Title | Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32231747 https://www.proquest.com/docview/2598340864 https://search.proquest.com/docview/2385275569 https://pubmed.ncbi.nlm.nih.gov/PMC7097940 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB4VkBCXFe_NwlYG7TVt6kedHHe7rQDRCm1B6i2y06koalNEi7T773fsJFWBGxcfEltJxt94ZuLxNwA_2m53yNoozLhUobRWhzZRpO7GtHg7IR3xlPn9QfvqQd6M1KgGqjoL45P2Mztt5LN5I58--tzK53nWrPLEmnf9jo4SglHU3IItAuhGiO6XX7L4ZBYLFiFN_k7zKTMN6Xhg9mCX8EsW0xVT2TRDH3zL9ymSGzantw9fSmeR_Sxe6gBqmB_Cbr_cDj-C6RD_st9liRNSeGbyMfMllpfICl7iJSszsZijBiiPW_3zHa_d0ZD1FXJe2WCRh8O5mc1YB6m5pYWAdRwsXo7hode971yFZe2EMJORWIVxxhNX-bKlI6v0BHlsBGo14Si4sEJJkwg15nwSOYdBCGW1sFYJiZHEBNviBLbzRY5fgY11Fo1b2DIoY8kNjUYTT8iP1BzJvRQBXFaiTJ8LioyUQgsn-pREn3rRB3BeCTkttWSZUugVC0lBlQzgYn2b8O02LUyOi1fqI2LFNX1KEsBpMSfrp1STGYB-M1vrDo47--0dgpTn0C4h9O3TI89gj7vQ2_-NOYft1csrfif_ZGXrhMqRrsPOr-7g7k_dR_nU9mVc90j9DyON6h0 |
link.rule.ids | 230,315,730,783,787,867,888,2228,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806,74073,74630 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB7xkEoviEdpw9OgXlO8fqyTE0ILaGl39wJIe4vsZFYFQZayi1T-PePEG7pF4pJD7CjJjGf8ecb-BuB722eHnONxLpSOlXMmdqkmc7e2Jdop2UhFmd8ftLs36udQD0PAbRK2Vc58YuWoi3HuY-THBNMTqQiAq5PHP7GvGuWzq6GExiIsex4uX8HADE0TY-E0-dMMWRMKGYI-x3e5_aE8Jcz8NPQOW_6_RfKfOediDVYDWGSntXbXYQHLDfjUD-nwTbi9wr_sLJQ4IYNntixYVWJ5gqzmJZ6wsBOLeWqAcNzqpep46Y-GNHcIvLLBuIyvHuz9PesgXXrkCFjHD4unL3BzcX7d6cahdkKcKy6ncZKL1Fe-bBnutBmhSKxEo0cCpZBOamVTqQshRtwDBim1M9I5LRVyhSm25RYsleMSvwErTM6LFrYsqkQJS0-jTUaEI41AgpcygqOZKLPHmiIjo6WFl3dG8s4qeUewOxNyFqxkkr3pNILDppnGt09a2BLHz9RHJloY-pU0gq-1Tpq3kMYJ_igTgZnTVtPBc2fPt5S3vysObcNT8kR8--PPOoCV7nW_l_UuB7924LPwa-0q_LILS9OnZ9wjQDJ1-9WoewV54N_I |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJ1W8IMZnYAODeA11_REnT9PWrWphqyrGpL1FdnIRQyMdayex_37nxM0oSLzkIXaU5O58_tl3_h3Ax8RHh5zjcSGUjpVzJnaZpuFu7VAkGY2RhjL_ZJZMztTnc30e8p-WIa1y7RMbR10uCr9HPiCYnkpFAFwNqpAWMT8c7139in0FKR9pDeU0HsKWUYnkPdg6OJrNv3Y7LpygAM2XLb2QISA0-FHYT8oTxGxOSv8gzb8TJv-YgcZP4HGAjmy_1fU2PMD6KfRPQnD8GVyc4m92GAqe0PBnti5ZU3B5iaxlKV6ykJfFPFFAOHx123Sc-oMi3R2Csmy2qOPTn_byko2QLsfkFtjIG8n1czgbH30bTeJQSSEuFJerOC1E5utgDg132lQoUivR6EqgFNJJrWwmdSlExT18kFI7I53TUiFXmGEiX0CvXtT4ClhpCl4OcWhRpUpYehptWhGqNAIJbMoIPqxFmV-1hBk5LTS8vHOSd97IO4KdtZDzMGaW-b2GI3jfNZO1-xCGrXFxQ31kqoWhX8kieNnqpHsLuSYCQ8pEYDa01XXwTNqbLfXF94ZR2_CM_BJ__f_Pegd9Mrn8eDr78gYeCb_wbvZidqC3ur7BXUInK_c2mN0dnOLlZQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sex+Differences+and+Adverse+Effects+between+Chemotherapy+and+Immunotherapy+for+Non-Small+Cell+Lung+Cancer&rft.jtitle=Journal+of+Cancer&rft.au=Tsiouda%2C+Theodora&rft.au=Sardeli%2C+Chrisanthi&rft.au=Porpodis%2C+Konstantinos&rft.au=Pilikidou%2C+Maria&rft.date=2020-01-01&rft.issn=1837-9664&rft.eissn=1837-9664&rft.volume=11&rft.issue=11&rft.spage=3407&rft.epage=3415&rft_id=info:doi/10.7150%2Fjca.40196&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1837-9664&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1837-9664&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1837-9664&client=summon |